8C60.0  Drug-induced myasthenia gravis International Classification of Diseases for Mortality and Morbidity Statistics, 11th Revision, v2025-01 Some drugs can have clear effects on Myasthenia Gravis, including Neuromuscular junction blockers, antibiotics, prednisone, chloroquine, D-penicillamine, interferons, and others. In rapid-onset drug-induced Myasthenia Gravis, myasthenic signs develop within days which rapidly disappear after drug withdrawal. Anti-Acetylcholinesterase antibodies are absent. This disorder may unmask a pre-existing neuromuscular transmission disorder or may exacerbate pre-existing Myasthenia Gravis, i.e. subclinical Myasthenia Gravis becomes manifest after drug treatment, or known MG becomes more severe. Certain drugs are linked with aggravation of Myasthenia Gravis, including pain management medications, tricyclic antidepressants and some antiepileptic medications, and should be used with caution.
postcoordination Add Stem and/or Extension codes to form a cluster code which adds detail to the condition.
Associated with  - multiple selections are allowed  [select]  PB20 Unintentional exposure to or harmful effects of opioids or related analgesics  PB21 Unintentional exposure to or harmful effects of sedative hypnotic drugs or other CNS depressants  PB22 Unintentional exposure to or harmful effects of psychostimulants  PB23 Unintentional exposure to or harmful effects of cannabinoids or hallucinogens  PB24 Unintentional exposure to or harmful effects of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs  PB25 Unintentional exposure to or harmful effects of antidepressants  PB26 Unintentional exposure to or harmful effects of antipsychotics  PB27 Unintentional exposure to or harmful effects of antiepileptics or antiparkinsonism drugs  PB28 Unintentional exposure to or harmful effects of other or unspecified drug, medicament or biological substance  PB29 Unintentional exposure to or harmful effects of multiple drugs, medicaments or biological substances  PH40 Exposure to or harmful effects of undetermined intent of opioids or related analgesics  PH41 Exposure to or harmful effects of undetermined intent of sedative hypnotic drugs or other CNS depressants  PH42 Exposure to or harmful effects of undetermined intent of psychostimulants  PH43 Exposure to or harmful effects of undetermined intent of cannabinoids or hallucinogens  PH44 Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs  PH45 Exposure to or harmful effects of undetermined intent of antidepressants  PH46 Exposure to or harmful effects of undetermined intent of antipsychotics  PH47 Exposure to or harmful effects of undetermined intent of antiepileptics or antiparkinsonism drugs – PH47.0 Harmful effects of or exposure to mixed antiepileptics, not elsewhere classified, undetermined intent – PH47.Z Undetermined intent: Harmful effects of and exposure to noxious substances: Drugs, medicaments or biological substances: Unspecified antiepileptics or antiparkinsonism drugs  PH48 Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances  PH49 Exposure to or harmful effects of undetermined intent of multiple drugs, medicaments or biological substances  PL00 Drugs, medicaments or biological substances associated with injury or harm in therapeutic use  PL01 Complementary or traditional medicines associated with injury or harm in therapeutic use  PL01.0 Complementary or traditional medicines associated with injury or harm in therapeutic use, Herbal Preparations or Formulas  PL01.1 Complementary or traditional medicines associated with injury or harm in therapeutic use, Dietary Supplements, Vitamins or Minerals  PL01.2 Complementary or traditional medicines associated with injury or harm in therapeutic use, Complementary or Traditional Medicines, not elsewhere classified  PL01.Y Other specified complementary or traditional medicines associated with injury or harm in therapeutic use  PL01.Z Complementary or traditional medicines associated with injury or harm in therapeutic use, unspecified  PL0Z Substances associated with injury or harm in therapeutic use, unspecified  PL13 Mode of injury or harm associated with exposure to a drug, medicament or biological substance  PL13.0 Overdose of substance, as mode of injury or harm  PL13.1 Underdosing, as mode of injury or harm  PL13.2 Drug-related injury or harm in the context of correct administration or dosage, as mode of injury or harm  PL13.3 Incorrect substance, as mode of injury or harm  PL13.5 Incorrect administration of drug or medicament, as mode of injury  PL13.6 Medication or substance that is known to be an allergen, as mode of injury or harm  PL13.7 Medication or substance that is known to be contraindicated for the patient, as mode of injury or harm  PL13.8 Expired or deteriorated medication or substance, as mode of injury or harm  PL13.9 Drug or substance interactions, as mode of injury or harm  PL13.A Inappropriate stoppage or discontinuation of drug, as mode of injury or harm  PL13.Y Other specified mode of injury or harm associated with exposure to a drug, medicament or biological substance  PL13.Z Mode of injury or harm associated with exposure to a drug, medicament or biological substance, unspecified  PL13.50 Incorrect route of drug or medicament, as mode of injury  PL13.51 Incorrect rate of drug or medicament, as mode of injury  PL13.52 Incorrect timing of drug or medicament, as mode of injury  PL13.53 Incorrect duration of drug or medicament, as mode of injury  PL13.5Y Other specified incorrect administration of drug or medicament, as mode of injury  PL13.5Z Incorrect administration of drug or medicament, as mode of injury, unspecified 
synonyms Drug-induced myasthenia gravis medicament-induced myasthenia gravis        
          
          
          
      
      Thank you for choosing Find-A-Code, please Sign In  to remove ads.